Frontlight ResearchEarly access
Active, not recruitingPhase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
Key facts
- Who runs it
- Brown University
- Where
- Providence, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 184 people, planned
- Started
- 19 Aug 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Doxazosin
- Placebo
- Record updated
- 23 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Male or female, 18 years of age
- Meet the DSM-5 criteria for AUD
- Desire to reduce or quit alcohol drinking
- Breath alcohol (BrAC) = 0.00 at each visit
- In good health as confirmed by medical history, physical examination and lab tests
- Willing to adhere to the study procedures
- Understand informed consent and questionnaires in English at an 8th grade level
Who cannot take part
- Current use of medication that may interact with doxazosin and/or yohimbine
- Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
- Treatment with any alpha-blocker
- Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication
- Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
- History of allergy to any alpha receptor blockers
- Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG
- Women who are breastfeeding or /positive urine test for pregnancy
- CrCl<60mL/min
- Suicide attempt in the last three months
- Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
- Baseline hypotension defined as BP reading lower than 90/60 mmHg
Where in United States
- Brown UniversityProvidence, United States
About the trial
What the trial wants to find out
The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
The 2 groups in the trial
- doxazosinTreatment being tested
16 mg, or maximum tolerated dose (MTD)
- placeboPlacebo, for comparison
matching placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD
- Record updated
- 23 September 2026